{
    "Trade/Device Name(s)": [
        "Wondfo Amphetamine Urine Test (AMP 300)",
        "Wondfo Methamphetamine Urine Test (MET 500)"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K122961",
    "Predicate Device Reference 510(k) Number(s)": [
        "K041822",
        "K033299"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "LAF"
    ],
    "Summary Letter Date": "December 21, 2012",
    "Summary Letter Received Date": "November 13, 2012",
    "Submission Date": "November 8, 2012",
    "Regulation Number(s)": [
        "21 CFR 862.3100"
    ],
    "Regulation Name(s)": [
        "Amphetamine Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "d-Amphetamine",
        "D(+)-Methamphetamine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup",
        "Dip Card"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow"
    ],
    "Methodologies": [
        "Competitive binding",
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo AMP 300 and MET 500 immunochromatographic urine assays for amphetamine and methamphetamine detection",
    "Indications for Use Summary": "Qualitative determination of d-Amphetamine and D(+)-Methamphetamine in human urine at defined cutoff concentrations; prescription use only and not intended for point-of-care; provides preliminary test results requiring confirmation by alternative chemical method",
    "fda_folder": "Toxicology"
}